(MENAFN- market Press Release) August 25, 2022 5:39 am - SAE media Group reports: The Ophthalmic Drugs conference will be focusing on developments in Gene Therapy for Ocular Diseases
The Ophthalmic drugs industry continues to expand year on year, with an ageing population there is continual demand for advancements in ophthalmic treatments. This year's Ophthalmic Drugs Conference will have a key focus on gene therapy and artificial intelligence with developments on the latest drug pipelines and clinical trials.
The conference will convene on 21 – 22 November 2022 in London, UK, this year attendees will hear from industry giants about the developments being made in the ophthalmics and gene therapy field.
Interested parties can register at - register by 30 September to save £100.
The 5th annual conference will have a more in-depth discussion about the Developments in Gene Therapy for Ocular Diseases, with presentations and keynote speakers.
Use of Antisense Oligonucleotides for the Treatment of Inherited Retinal Diseases
•Antisense oligonucleotides have shown much promise in Ph1/2 Clinical Trials in LCA10 and Usher's Syndrome
•Lessons learned from Ph 2/3 trial with Sepofarsen for LCA10
•Latest trial data from Interim Analyses for Ultevursen for Usher's syndrome and non-syndromic Retinitis Pigmentosa
Led by: Aniz Girach, Chief Medical Officer, ProQR Therapeutics
Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy
•LHON, a rare disease with high unmet medical need
•Development of Lumevoq Gene Therapy to treat ND4 LHON patients Developments in Gene Therapy for Ocular Diseases Drug Delivery Regulatory pathways
•Key learnings from recent data
Led by: Magali Taiel, Chief Medical Officer, Gensight Biologics
Ocular Inflammation associated with Gene and Cell Therapy
•Immune privilege and the eye
•Inflammation and gene therapy
•Inflammation and cell-based therapy
•What to look for….
Led by: Virginia Calder, Professor of Ocular Immunology, University College London
Strengthening the Therapeutic Landscape for Inherited Retinal Diseases Using Genome Editing with AAV Vectors & CRISPR/Cas9 Technologies
•Expanding on the clinical development of novel gene therapies including SPVN06
•The benefits of designing gene therapies to act independently of the causative gene mutation
•An introduction to new clinical trials and future workings
Led by: Daniel Chung, Chief Medical Officer, Sparing Vision
To find out more about the line – up of the esteemed speakers for the conference and to download a complimentary brochure please visit
For sponsorship enquiries contact Andrew Gibbons on +44 (0) 20 7827 6156 or email:
For media enquiries or a press pass contact Marketing, Simi Sapal on +44 (0) 20 7827 6162 or email
Ophthalmic Drugs
21-22 November 2022
London, UK
#OphthalmicDrugs
Sponsor: The Technology Partnership | Celanese
--- ENDS ---
About SAE Media Group Conferences:
SAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace, Pharmaceutical and Medical. Each year we bring together over 5,000 senior business professionals at our conferences. Media Group (SMG), a subsidiary of SAE International, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.
MENAFN26082022003520003262ID1104759469
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.